Michael Thomas Heffernan, insider filing for TRVI
Michael Thomas Heffernan, reporting
TRVI
Trevi Therapeutics, Inc. SEC filings
Every EDGAR filing for Trevi Therapeutics, Inc. (TRVI), newest first, with AI summaries and stories.
- Ticker
- TRVI
- CIK
- 1563880
- Latest filing
- Sep 17
Next: earnings expected ~Nov 9 · 10-Q expected ~Nov 9 (deadline Nov 16)
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
ROUTINE4Trevi Therapeutics, Inc.TRVILIVE ROUTINE144Trevi Therapeutics, Inc.TRVILIVE Michael Thomas Heffernan, planned sale of TRVI shares
Michael Thomas Heffernan, reporting
ROUTINES-8Trevi Therapeutics, Inc.TRVILIVE NOTABLE10-QTrevi Therapeutics, Inc.TRVILIVE ROUTINE8-KTrevi Therapeutics, Inc.TRVILIVE ROUTINESCHEDULE 13G/ATrevi Therapeutics, Inc.TRVILIVE Ownership stake disclosure by FMR LLC (amended)
FMR LLC, filed by
ROUTINE4Trevi Therapeutics, Inc.TRVILIVE 5 insider filings
Edward T Mathers, insider filing for TRVI
Show all 5
- 4Insider filing for TRVI
- 4Insider filing for TRVI
- 4Insider filing for TRVI
- 4Insider filing for TRVI
- 4Insider filing for TRVI
Edward T Mathers, reporting
ROUTINE8-KTrevi Therapeutics, Inc.TRVILIVE NOTABLESCHEDULE 13D/ATrevi Therapeutics, Inc.TRVILIVE Ownership stake disclosure by New Enterprise Associates 16, L.P. (amended)
New Enterprise Associates 16, L.P., filed by
ROUTINESCHEDULE 13G/ATrevi Therapeutics, Inc.TRVILIVE Ownership stake disclosure by FMR LLC (amended)
FMR LLC, filed by
NOTABLE10-QTrevi Therapeutics, Inc.TRVILIVE ROUTINE8-KTrevi Therapeutics, Inc.TRVILIVE ROUTINEDEF 14ATrevi Therapeutics, Inc.TRVILIVE ROUTINEDEFA14ATrevi Therapeutics, Inc.TRVILIVE ROUTINEARSTrevi Therapeutics, Inc.TRVILIVE ROUTINE424B5Trevi Therapeutics, Inc.TRVILIVE ROUTINE8-KTrevi Therapeutics, Inc.TRVILIVE ROUTINE424B5Trevi Therapeutics, Inc.TRVILIVE ROUTINEPRE 14ATrevi Therapeutics, Inc.TRVILIVE ROUTINESCHEDULE 13G/ATrevi Therapeutics, Inc.TRVILIVE Ownership stake disclosure by VANGUARD GROUP INC (amended)
VANGUARD GROUP INC, filed by
NOTABLE10-KTrevi Therapeutics, Inc.TRVILIVE ROUTINE8-KTrevi Therapeutics, Inc.TRVILIVE ROUTINE8-KTrevi Therapeutics, Inc.TRVILIVE ROUTINE4Trevi Therapeutics, Inc.TRVILIVE 5 insider filings
James V Cassella, insider filing for TRVI
Show all 5
- 4Insider filing for TRVI
- 4Insider filing for TRVI
- 4Insider filing for TRVI
- 4Insider filing for TRVI
- 4Insider filing for TRVI
James Cassella V, reporting
ROUTINE5Trevi Therapeutics, Inc.TRVILIVE 8 insider filings
Scott D Sandell, annual insider report for TRVI
Show all 8
- 5Annual insider report for TRVI
- 5Annual insider report for TRVI
- 5Annual insider report for TRVI
- 5Annual insider report for TRVI
- 5Annual insider report for TRVI
- 5Annual insider report for TRVI
- 5Annual insider report for TRVI
- 5Annual insider report for TRVI
Scott D Sandell, reporting
ROUTINESCHEDULE 13G/ATrevi Therapeutics, Inc.TRVILIVE Ownership stake disclosure by Rubric Capital Management LP (amended)
Rubric Capital Management LP, filed by
NOTABLESCHEDULE 13D/ATrevi Therapeutics, Inc.TRVILIVE Ownership stake disclosure by New Enterprise Associates 16, L.P. (amended)
New Enterprise Associates 16, L.P., filed by
ROUTINESCHEDULE 13GTrevi Therapeutics, Inc.TRVILIVE Ownership stake disclosure by FMR LLC
FMR LLC, filed by
ROUTINESCHEDULE 13GTrevi Therapeutics, Inc.TRVILIVE Ownership stake disclosure by VANGUARD GROUP INC
VANGUARD GROUP INC, filed by
ROUTINE4Trevi Therapeutics, Inc.TRVILIVE 2 insider filings
David C Hastings, insider filing for TRVI
Show all 2
- 4Insider filing for TRVI
- 3New insider at TRVI
David C Hastings, reporting
ROUTINE8-KTrevi Therapeutics, Inc.TRVILIVE ROUTINE4Trevi Therapeutics, Inc.TRVILIVE Christopher Galletta, insider filing for TRVI
Christopher Galletta, reporting
ROUTINESCHEDULE 13G/ATrevi Therapeutics, Inc.TRVILIVE Ownership stake disclosure by VIKING GLOBAL INVESTORS LP (amended)
VIKING GLOBAL INVESTORS LP, filed by
ROUTINES-3ASRTrevi Therapeutics, Inc.TRVILIVE Trevi Therapeutics, Inc. (TRVI) filed a Form S-3 registration statement to establish a shelf offering program, providing the company flexibility to raise capital as needed to fund its ongoing drug development efforts.